Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs (Neu I)
The aim of this placebo controlled study is to investigate the effect of 2 mg melatonin Slow Release (Circadin®) on the sleep/wake cycle in elderly insomniac out-subjects, aged 55 years or more.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||Phase II Study of Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs.|
|Study Start Date:||September 1996|
|Study Completion Date:||September 1997|
|Primary Completion Date:||May 1997 (Final data collection date for primary outcome measure)|
|Placebo Comparator: placebo||
Drug: placebo Circadin
Placebo tabs of Prolonged release melatonin
prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
Other Name: ATC code: N05CH01
Circadin® is a newly developed slow release galenic formulation of melatonin, producing overall levels of melatonin comparable to those observed in a control population, when administered to patients with deficiency in melatonin; thus it deserves more clinical and paraclinical investigations for establishing efficacy in inducing and maintaining sleep and for safety. Since, on the one hand, the endogenous substance melatonin has beneficial effects on sleep in man and, on the other hand, there is a decrease in melatonin secretion in elderly people, substitution therapy in elderly insomniacs would be a desirable therapy.
The aim of this placebo controlled study was to investigate the effect of 2 mg Melatonin Slow Release (Circadin®) on the sleep/wake cycle in elderly insomniac out-subjects, aged 55 years or more. Sleep was assessed by means of polysomnography (hypnographic results), all-night sleep EEG spectral analysis (functional and quantitative results of sleep EEG), actimetry (SomnitorTM), wake EEG and sleep/wake quality questionnaires. Vigilance and cognitive skills were assessed by means of psychomotor and neurocognitive tests derived from the Leeds psychomotor test battery (vigilance and arousal) and TEA battery (attention).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00816673
|Centre Hospitalier de Rouffach, France, F-68250|
|Principal Investigator:||Jean Paul MACHER, MD||Forenap|